

## DAFTAR PUSTAKA

1. WHO. Cancer [Internet]. [dikutip 5 Maret 2020]. Tersedia pada: <https://www.who.int/news-room/fact-sheets/detail/cancer>
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6): 394–424.
3. Globocan Observatory W. Cancer Today - World. *Int Agency Res Cancer.* 2019;876:2018–9.
4. Zhao Y, Wang Y, Ma S. Racial Differences in Four Leukemia Subtypes: Comprehensive Descriptive Epidemiology. *Sci Rep.* Januari 2018;8(1):548.
5. Fadjari H, Sukrisman L. Leukemia Granulositik Krinik. In: Setiati S, Alwi I, Sudoyo AW, K MS, Setiyohadi B, Syam AF, editor. *Buku Ajar Ilmu Penyakit Dalam.* 6 ed. Jakarta: internapublishing; 2017. hal. 2680–4.
6. Nowell PC. National Academy of Sciences. *Proc Natl Acad Sci U S A.* 1968;60(3):1985.
7. John MG, George QD. Chronic Myeloid Leukemia — A Brief History [Internet]. *Springe Nature.* [dikutip 9 Maret 2020]. Tersedia pada: [https://link.springer.com/chapter/10.1007/978-3-540-34506-0\\_1](https://link.springer.com/chapter/10.1007/978-3-540-34506-0_1)
8. Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The philadelphia chromosome in leukemogenesis. *Chin J Cancer.* 2016;35(1): 1–15.
9. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: A retrospective analysis of the Surveillance, Epidemiology and End Results database. *Ther Adv Hematol.* 2015;6(6):308–12.
10. Jabbour E. Annual Clinical Updates in Hematological Chronic myeloid leukemia: 2018 update on diagnosis , therapy and monitoring. 2018; (December 2017):442–59.

11. Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017;28 (Supplement 4):iv41–51.
12. Rina , E. Eden; Coviello JM. Cancer, Chronic Myelogenous Leukemia (CML, Chronic Granulocytic Leukemia) [Internet]. [dikutip 14 Maret 2020]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK531459/>
13. Greenfield G, McMullan R, Robson N, McGimpsey J, Catherwood M, McMullin MF. Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. *BMC Hematol.* 2019;19(1):1–9.
14. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. *Blood.* Maret 2016;127(10):1269–75.
15. Menteri Kesehatan. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/068/I/2010 tentang Kewajiban Menggunakan Obat Generik di Fasilitas Pelayanan Kesehatan Pemerintah.
16. Menteri Kesehatan. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/659/2017 tentang Formularium Nasional. Jakarta; 2017.
17. Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. *Front Oncol.* 2019;9(OCT):1–18.
18. Emmanuel C Besa M. Chronic Myelogenous Leukemia (CML) [Internet]. Medscape. [dikutip 16 Maret 2020]. Tersedia pada: <https://emedicine.medscape.com/article/199425-overview>
19. Frazer R, Irvine AE, McMullin MF. Chronic Myeloid Leukaemia in The 21st Century. *Ulster Med J.* 2007;76(1):8–17.
20. Bakta IM. Hematologi Klinik Ringkas. Jakarta: EGC; 2006. hal. 137–144

21. Hsu W-L, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. *Radiat Res.* Maret 2013;179(3):361–82.
22. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. *Blood.* Januari 2016;127(4):392–9.
23. Cortes jorge E, Silver richard T, Khoury H jean, Kantarjian hagop M. Chronic Myeloid Leukemia [Internet]. Cancer Network Home of the Journal Oncology. [dikutip 19 Maret 2020]. Tersedia pada: <https://www.cancernetwork.com/chronic-myeloid-leukemia/chronic-myeloid-leukemia>
24. American Cancer Society. Chronic Myeloid Leukemia Causes , Risk Factors , and Prevention Risk Factors for Chronic Myeloid Leukemia What Causes Chronic Myeloid Leukemia ? *Am Cancer Soc.* 2018;(CML):1–10.
25. Winslow T. Philadelphia Chromosome [Internet]. 2007. Tersedia pada: <https://www.teresewinslow.com/cellular-scientific/9vavdk7xuvvhib624d8sjknlrkd9in>
26. Mandal A. What are Genes? *News Med* [Internet]. 2016;1–15. Tersedia pada: <http://www.news-medical.net/life-sciences/What-are-Genes.aspx>
27. Chun C. Proto-Oncogenes Explained [Internet]. [dikutip 20 Maret 2020]. Tersedia pada: <https://www.healthline.com/health/proto-oncogene#vs-oncogene>
28. Wang JYJ. The Capable ABL: What Is Its Biological Function? *Mol Cell Biol.* 2014;34(7):1188–97.
29. Paul MK, Mukhopadhyay AK. Tyrosine kinase – Role and significance in Cancer. *Int J Med Sci.* 2012;1(283):101–15.
30. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi S-A, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. *Arch Iran Med.* Mei 2008;11(3): 247–51.

31. Tabassum N, Saboor M, Ghani R, Moinuddin M. Heterogeneity of breakpoint cluster region-Abelson (BCR-ABL) rearrangement in patients with chronic myeloid leukemia. *Pakistan J Med Sci.* 2014;30(4):850–3.
32. Goldman JM, Melo J V. Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment. *N Engl J Med.* Oktober 2003;349(15):1451–64.
33. Todoric-Zivanovic B, Strnad M, Stamatovic D, Tukic L, Krtolica K, Tatomirovic Z, et al. Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia. *J BUON.* 2011;16(1):104–7.
34. Jennifer C, Pankaj B, Amandeep G, Alexandre MA. Splenomegaly [Internet]. [dikutip 23 Maret 2020]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK430907/>
35. Manish P. Splenic Infarct [Internet]. Medscape. [dikutip 23 Maret 2020]. Tersedia pada: <https://emedicine.medscape.com/article/193718-overview>
36. Buzaid AN, Amri AM Al, E SA. Sudden Visual Loss as an Initial Manifestation of Chronic Myeloid Leukemia. 2017;278–80.
37. Huang PK, Sanjay S. Visual Disturbance as the first Symptom of Chronic Myeloid Leukemia. *Middle East Afr J Ophthalmol.* Oktober 2011;18(4): 336–8.
38. Tazi I. Priapism as the first manifestation of chronic myeloid leukemia. *Ann Saudi Med.* 2009;29(5):412.
39. Nerli RB, Magdum P V, Hiremath SC, Patil AY, Pai S V, Handigund RS, et al. Urology Case Reports Priapisme A Rare Presentation in Chronic Myeloid Leukemia : Case Report. *Urol Case Reports.* 2016;4:8–10.
40. Bennour A, Ouahchi I, Achour B, Zaier M, Youssef Y Ben, Khelif A, et al. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. *Med Oncol.* 2012;30(1):348.
41. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. *Blood.* Januari 1990;75(2):445–52.



42. Bhagavathi S, Borromeo V, Desai H, Crisan D. Case report and literature review: A rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. *Ann Clin Lab Sci*. Februari 2008;38:405–9.
43. Davis AS, Viera AJ, Mead MD. Leukemia: An overview for primary care. *Am Fam Physician*. 2014;89(9):731–8.
44. Hato A, Murayama T, Nishikawa S, Kajimoto K, Gomyo H, Sugimoto T, et al. Philadelphia chromosome positive acute lymphoblastic leukemia showing normal karyotype in G-banding chromosomal examination before chemotherapy. *Hematology*. Oktober 2005;10(5):379–81.
45. Yadav AK, Bhargava M. Philadelphia Chromosome by karyotype [Internet]. [dikutip 8 April 2020]. Tersedia pada: <https://imagebank.hematology.org/image/61436/philadelphia-chromosome-by-karyotype>
46. Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valgañón M, Chanalaris A, et al. FISH mapping of Philadelphia negative BCR/ABL1 positive CML. *Mol Cytogenet*. Juli 2008;1:14.
47. Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical <em>BCR-ABL</em> mRNA transcripts in adult Acute lymphoblastic leukemia. *Haematologica*. Desember 2007;92(12): 1699 LP – 1702.
48. Khalaf R. Chronic Myelogenous Leukemia (CML) Treatment Protocols [Internet]. Medscape. [dikutip 9 April 2020]. Tersedia pada: <https://emedicine.medscape.com/article/2005453-overview>
49. Drozd-Sokołowska JE, Waszczuk-Gajda A, Mądry K, Dwilewicz-Trojaczek J. Atypical chronic myeloid leukaemia – A rare subtype of myelodysplastic/myeloproliferative neoplasm. *Wspolczesna Onkol*. 2018;22(1):14–9.
50. Gotlib J. How I treat atypical chronic myeloid leukemia. *Blood*. Februari 2017;129(7):838–45.
51. Kolibaba KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia [Internet]. Medscape. [dikutip 9 April 2020]. Tersedia pada: [https://www.medscape.com/viewarticle/408451\\_6](https://www.medscape.com/viewarticle/408451_6)

52. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood*. Maret 2012;119(9):1981–7.
53. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. *Cancer*. 2002;95(8):1673–84.
54. Rajabto W, Harryanto A, Tadjoeidin H, Harimurti K. Hubungan Gambaran Klinis dan Laboratorium Hematologis antara Leukemia Granulositik Kronik Ph (+)/BCR-ABL (+) dengan Bentuk Kelainan Ph/BCR-ABL Lainnya. *J Penyakit Dalam Indones*. 2018;5(1):11.
55. Aisyi M, Lestari P, Nadliroh S, Meisita A, Solachudin D, Kristanti D, et al. The Profile of BCR-ABL1 Fusion Gene in Childhood Leukemia at “Dharmais” Cancer Hospital. *Indones J Cancer*. 2020;14(3):86.
56. Pathak R, Giri S, Martin MG, Bhatt VR. Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database. *J Clin Oncol*. Mei 2015;33(15\_suppl):e18053–e18053.
57. Ali FB, Verma RK, Ali M, Kumar N. The Prevalence of Philadelphia Chromosome in BCR-ABL Positive Chronic Myelogenous Leukemia Cases in North Indian Population. *Int J Curr Pharm Rev Res*. 2017; (January).
58. Ayatollahi H, Keramati MR, Shirdel A, Kooshyar MM, Raiszadeh M, Shakeri S, et al. BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran. *Casp J Intern Med*. 2018;9(1):65–70.
59. Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression. *Hematol Rep*. Januari 2011; 3(1):e3–e3.

60. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. *Leukemia*. 2008;22(7): 1308–19.
61. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Vol. 91, *Haematologica*. Italy; 2006. hal. 1566–8.
62. Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. *Leukemia*. Juni 2015;29(6):1336–43.
63. Khazaal MS, Hamdan FB, Al-Mayah QS. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients. *Mol Genet Genomic Med*. 2019;7(8):1–9.
64. Kong JH, Nam H, Go T-H, Hyun SY, Shim KY. Characteristics and survival of patients with atypical chronic myeloid leukemia. *Blood Res*. September 2019;54(3):233–6.
65. Hernández JM, del Cañizo MC, Cuneo A, García JL, Gutiérrez NC, González M, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. *Ann Oncol*. 2000;11(4):441–4.
66. Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS, et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. *Indian J Med Paediatr Oncol*. Januari 2014;35(1):26–30.
67. de Almeida Filho TP, Maia Filho PA, Barbosa MC, Dutra LLA, Castro MF de, Duarte FB, et al. Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? *Hematol Transfus Cell Ther*. 2019;41(2):114–8.

68. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. *Haematologica*. September 2014;99(9):1441–7.
69. Rosas-Cabral A, Martínez-Mancilla M, Ayala-Sánchez M, Vela-Ojeda J, Bahena-Reséndiz P, Vadillo-Buenfil M, et al. Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia. *Gac Med Mex*. 2003;139(6):553–9.
70. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, et al. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. *Eur J Haematol*. Februari 2009;82(2):112–8.
71. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. *Blood*. September 2009;114(11):2232–5.
72. Léglise MC, Pluchon-Rivière E, Le Calvez G, Abgrall JF, Berthou C, Autrand C, et al. Molecular diagnosis and follow up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia. *Leuk Lymphoma*. April 1996;21(3–4):187–99.

